Therapeutics News

Forty-two patients in a single-center, open-label study showed improvements in fluorescein staining as well as reductions in dryness, grittiness and discomfort after 2 weeks of using Retaine ophthalmic emulsion, researchers reported in Clinical Ophthalmology.

By using a specific strategy, some patients with hypertension but a low risk of developing glaucoma may be able to reduce their medications, researchers reported in a study recently published in the British Journal of Ophthalmology.

The number of eye drops and eye drops containing benzalkonium chloride may contribute to the prevalence of ocular surface disease in glaucoma patients, according to a study recently published in Optometry and Vision Science.

ATLANTA – During a special session on advances in cataract surgery here at SECO, Bret Fisher, MD, discussed a proprietary compound of two antibiotics and a steroid injected transzonularly into the anterior vitreous at the time of surgery. 

ATLANTA – Alcon’s new once daily Pazeo will be commercially available March 10, announced a company representative during a press conference here at SECO.

Patients who switched to generic latanoprost were more likely to adhere to their drug regimens, according to a study recently published in Ophthalmology.

Following glaucoma surgery in one eye, researchers found that intraocular pressure rose in the fellow eye, according to a study recently published in the Journal of Glaucoma.

Researchers determined that 50% autologous serum eye drops were both effective and safe as a long-term treatment option for dry eye disease in a study recently published in Cornea.

Envisia Therapeutics has initiated a phase 2a clinical trial of ENV515, a possible treatment for patients with glaucoma, the company announced in a press release.

The U.S. Food and Drug Administration has granted U.S. marketing approval to Pazeo, a solution for ocular allergy itch relief from Alcon.